Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
UBS
Chubb
Teva
Johnson and Johnson
Deloitte

Generated: September 22, 2019

DrugPatentWatch Database Preview

Patent: 7,611,702

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,611,702
Title:TNF-alpha blocker treatment for enterocolitis associated with immunostimulatory therapeutic antibody therapy
Abstract: The present invention provides methods for treating adverse events related to immunotherapy. More specifically, the present invention provides methods for treating the enterocolitis associated with anti-CTLA-4 antibody immunotherapy.
Inventor(s): Fischkoff; Steven (Short Hills, NJ), Lowy; Israel (Dobbs Ferry, NY), Yellin; Michael (Montclair, NJ), Yang; James Chung-Yin (Silver Spring, MD)
Assignee: Medarex, Inc. (Princeton, NJ)
Application Number:11/557,835
Patent Claims:see list of patent claims

Details for Patent 7,611,702

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Centocor Inc REMICADE infliximab VIAL 103772 001 1998-08-24   Try a Free Trial Medarex, Inc. (Princeton, NJ) 2025-11-08 RX Orphan search
Immunex ENBREL etanercept VIAL; SUBCUTANEOUS 103795 001 1998-11-02   Try a Free Trial Medarex, Inc. (Princeton, NJ) 2025-11-08 RX Orphan search
Immunex ENBREL etanercept SYRINGE 103795 002 1998-11-02   Try a Free Trial Medarex, Inc. (Princeton, NJ) 2025-11-08 RX Orphan search
Abbvie Inc HUMIRA adalimumab SYRINGE 125057 001 2002-12-31   Try a Free Trial Medarex, Inc. (Princeton, NJ) 2025-11-08 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Accenture
Daiichi Sankyo
Moodys
Argus Health
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.